Semaglutide

79 trials 31 recruiting AGastroenterology

Filter these 79 trials by condition, phase, country and more.

Open in Search →

79 Registered trials

31 Recruiting

31 Completed trials

44 Sponsors

24 Countries

Phase III

Phase II

Phase IV

Phase III: 21 Phase II/III: 1 Phase II: 24 Phase III/IV: 4 Phase IV: 27 Phase I (Other): 1 Other: 1

Oversight events:

8 serious breaches 1 temporary halt across 6 trials

View oversight register →

Indications tested

Obesity 10 Type 2 diabetes mellitus 5 Non-alcoholic steatohepatitis 3 Chronic kidney disease 3 Overweight 3 Diabetes mellitus 2 Acute coronary syndrome 1 Coronary artery disease 1 Multiple sclerosis 1 Palpitations 1 Atrial fibrillation 1 Alcoholic liver disease 1

Sponsors using this IMP

Novo Nordisk A/S 19 Region Hovedstaden 5 Rigshospitalet 5 Region Midtjylland 3 Steno Diabetes Center Copenhagen 3 Aarhus University Hospital 2 Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca 2 Karolinska University Hospital 2 Odense University Hospital 2 University College Dublin 2 UZ Leuven 2 AstraZeneca AB 1

All trials — page 4

79 total

A research study investigating how semaglutide and dapagliflozin act in your body when dosed in one tablet Ended

2022-500007-52-00 1 country Novo Nordisk A/S
Research study on whether a combination of 2 medicines (NNC0194-0499 and Semaglutide) works in people with non-alcoholic steatohepatitis (NA… Ended

2023-506961-74-00 Phase II 11 countries Novo Nordisk A/S
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Phase III 21 countries Novo Nordisk A/S
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Phase III 21 countries Novo Nordisk A/S
PIONEER TEENS. A research study to compare a new medicine oral semaglutide to a dummy medicine in children and teenagers with type 2 diabete… Ended

2023-506923-27-00 Phase III 6 countries Novo Nordisk A/S
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5) Ended

2022-501106-35-00 Phase III 3 countries Eli Lilly & Co.
SemaPsychiatry Ended

2024-518746-24-00 Phase II 1 country Psykiatrisk Center Kobenhavn

Showing 73–79 of 79 trials

← All drugs A–Z